MALAT1 and breast carcinoma: Therapeutic targeting of the PI3K/Akt pathway and nuclear retention of FOXO1 could suppress the upregulation of MALAT1, re-sensitize the sensitivity of trastuzumab, and prevent breast cancer progression.